Developer docs
API playgroundTry for free, no card

Search company profiles

Stereotaxis

Full company profile

uuid0000qon

Namestring
Stereotaxis
Legal namestring
Stereotaxis, Inc.
Websiteurl
stereotaxis.com
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Stereotaxis is a St. Louis-based medical technology company founded in 1990 that develops robotic systems for minimally invasive endovascular procedures, with its primary application in cardiac ablation to treat arrhythmias. Its core technology, Robotic Magnetic Navigation (RMN), uses computer-controlled magnetic fields to navigate catheters inside the heart with precision, stability, and reduced radiation exposure, differentiating it from manual catheter ablation. The company sells capital equipment — the Genesis RMN System and the newer semi-mobile GenesisX System — to hospitals and electrophysiology labs globally. These systems are complemented by a proprietary consumable catheter portfolio (MAGiC ablation catheter, MAGiC Sweep high-density mapping catheter, and Map-iT diagnostic catheters acquired via the 2024 Access Point Technologies deal) that drives recurring procedure-based revenue under a razor/razor-blade model. More recently, Stereotaxis has expanded into a digital surgery ecosystem with the Synchrony platform (FDA-cleared April 2026), which aggregates cath lab systems onto a consolidated 4K display, and the SynX cloud app for HIPAA/GDPR-compliant remote connectivity, training, and collaboration, opening a subscription revenue stream. Customers are hospitals and electrophysiology labs across more than 100 sites in the US, Europe, and Asia, sold through a direct enterprise field sales force supplemented by a strategic partnership with Shanghai MicroPort EP Medtech for China.

The business model combines one-time capital equipment sales, recurring single-use catheter consumables, and emerging subscription software revenue. The company is unprofitable but improving — operating losses narrowed to approximately ($22.1M) in 2025 from ($24.7M) in 2024 on revenue of $32.4M (up 20% YoY), with 2026 guidance above $40M. Capital has been raised through a $15M Consonance Capital financing in 2020, a $12.5M registered direct offering in July 2025, and a $50M ATM facility with Roth Capital in August 2025. The announced acquisition of Robocath (April 2026, up to $45M) would extend the platform into interventional cardiology and neurointerventions, and a collaboration with CardioFocus (October 2025) targets robotic Pulsed Field Ablation, a next-generation energy modality. CEO David Fischel has led the company since 2019 under a Tesla-inspired performance-based compensation structure.

Short descriptiontext

Stereotaxis develops robotic magnetic navigation systems and proprietary catheters for minimally invasive cardiac ablation, serving 100+ hospitals globally through direct enterprise sales supplemented by recurring catheter consumables and emerging digital surgery software.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
robotic magnetic navigation, cardiac ablation systems, electrophysiology catheters, surgical robotics, interventional cardiology devices
Industry3 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHACAH
Remote Patient Monitoring (RPM) Platforms & Device Hubs (Connectivity/Gateways)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Robotics for Cardiac Electrophysiology
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Robotic Surgical Systems
TypeHardware Sales
Description

Capital equipment sales of Genesis and GenesisX robotic magnetic navigation systems to hospitals. Systems represent significant upfront capital expenditure for hospital cath labs.

biospace.com
2Catheter Consumables
TypeSubscription Recurring
Description

Recurring revenue from proprietary ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in procedures with robotic systems. Razor/razor-blade model driving recurring consumable sales.

biospace.com
3Digital Surgery Software/Services
TypeSubscription Recurring
Description

Revenue from Synchrony digital surgery platform and SynX cloud connectivity services. Company expects more than $3 million in standalone SynX revenues.

mpo-mag.com
4Stock Sales (ATM Facility)
TypeOne Time License
Description

Sales Agreement with Roth Capital Partners allowing sale of up to $50 million worth of common stock for working capital, R&D, and commercialization.

sec.gov
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Pricing details3 tiers
1Capital equipment - Robotic systems
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Genesis and GenesisX robotic magnetic navigation systems sold as capital equipment to hospitals. Pricing varies by configuration and hospital requirements. Quote-based sales process.

sec.gov
2Catheter consumables
ModelUnit PricingBilling cadencePay-as-you-go
Notes

MAGiC ablation catheters, MAGiC Sweep mapping catheters, and Map-iT diagnostic catheters sold as single-use consumables. Recurring revenue per procedure.

biospace.com
3SynX cloud connectivity
ModelSubscriptionBilling cadenceAnnual
Notes

SynX cloud-based remote connectivity services provided as subscription. Company expects more than $3 million in standalone SynX revenues.

tradingview.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Genesis
Description

Robotic Magnetic Navigation System - designed as a powerful robotic magnetic navigation system with unprecedented responsiveness to physician control

stereotaxis.com
+8 more records
Core offering1 text field

Stereotaxis develops and sells Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—that use computer-controlled magnetic fields to navigate electrophysiology catheters inside the heart with precision and stability. The company also sells proprietary single-use ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in conjunction with the robotic systems, as well as the Synchrony digital surgery platform and SynX cloud connectivity app. These offerings are sold primarily to hospitals and cardiac electrophysiology labs for minimally invasive treatment of arrhythmias and coronary artery disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 150,000 patients treated globally with robotic technology
+4 more records
Product overview1 text field

Stereotaxis is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. The company's portfolio centers on Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—which use computer-controlled magnetic fields to precisely navigate catheters during cardiac ablation procedures. Complementing the robotic systems are differentiated catheters including MAGiC ablation catheters, MAGiC Sweep mapping catheters, and Map-iT diagnostic catheters (from the Access Point Technologies acquisition). The Synchrony digital surgery platform aggregates cath lab systems onto consolidated 4K displays, paired with the cloud-based SynX app for remote connectivity and collaboration. Together, these products form a comprehensive ecosystem addressing the interventional laboratory from robotic navigation to digital surgery enablement.

Product and service7 records
1Genesis Robotic Magnetic Navigation System
CategoryRobotic Surgical System
Description

The most powerful Robotic Magnetic Navigation System by Stereotaxis, featuring magnets held on flexible robotic arms for unprecedented physician control, increased system angulation, and improved performance and reliability compared to prior RMN systems. Sold as capital equipment to hospitals with electrophysiology labs.

2GenesisX Robotic Magnetic Navigation System
CategoryRobotic Surgical System
Description

Next-generation semi-mobile Robotic Magnetic Navigation System combining Genesis speed and responsiveness with a form factor deployable in a cath lab over a weekend with no lab modifications required. Magnetic fields are shielded within the base when parked, allowing unrestricted use of the room.

3Synchrony System
CategoryDigital Surgery Platform
Description

Digital surgery platform that aggregates all cath lab systems and procedural information onto a consolidated 55-inch 4K ultra-high-definition display. Enables complete control of disparate systems through a single keyboard and mouse, declutters the lab environment, and supports future technological integration.

4SynX Cloud-Based System
CategoryCloud Connectivity Software
Description

Cloud-based app integrating with Synchrony display system for high-fidelity low-latency transmission of all lab information. Enables remote procedure monitoring, training, support, and collaboration in HIPAA/GDPR-compliant fashion requiring minimal hardware.

5MAGiC Magnetic Interventional Ablation Catheter
CategoryElectrophysiology Catheter
Description

The world's first robotically navigated magnetic RF ablation catheter. Used with Stereotaxis robotic systems to provide catheter precision, stability, and flexibility for diagnosing and treating cardiac arrhythmias. Sold as single-use consumable driving recurring razor-blade revenue.

6MAGiC Sweep Mapping Catheter
CategoryElectrophysiology Mapping Catheter
Description

The world's first robotically navigated high-density EP mapping catheter with 20 electrodes for rapid and highly detailed electroanatomical mapping. Enables mapping of complex anatomy with the inherent safety of an atraumatic catheter. Not CE marked; not available for sale in Europe.

7Map-iT Diagnostic Catheters
CategoryDiagnostic EP Catheters
Description

Portfolio of differentiated high-quality diagnostic EP catheters acquired through Access Point Technologies. Proprietary designs with quality materials and refined manufacturing deliver performance and durability for treating complex arrhythmias.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Stereotaxis acquiring Robocath, a France-based surgical robot developer, for up to $45 million ($20M upfront + $25M contingent). Robocath develops R-One+ robotic technology for interventional cardiology and neurointerventions - the only robot commercially available in Europe for PCI. Expected to close mid-2026, operating as subsidiary.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-13
Description

Collaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-13
Description

Stereotaxis acquired Access Point Technologies, a Minnesota-based developer and manufacturer of electrophysiology catheters. Transaction closed July 31, 2024. Acquisition enhances in-house catheter manufacturing capabilities, contributing approximately $5 million in annual revenue.

4Abbott
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-24
Description

Global collaboration combining Abbott's leading cardiac mapping systems (EnSite X, Ensite X EP System, AcQMap) with Stereotaxis' advanced robotic magnetic navigation technology. First integrated procedures completed in US at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.

stereotaxis.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-08-31
Description

Strategic relationship with Shanghai MicroPort EP Medtech Co. Ltd. for China market expansion. China described as new 'geographic pillar' for commercial efforts. MicroPort joint venture with Robocath formed CathBot for vascular intervention robotics.

6Osypka AG
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-05-09
Description

Broad strategic collaboration with Osypka AG for designing and developing next-generation magnetic ablation catheter to be navigated using Stereotaxis' robotic technology.

stereotaxis.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French developer of the R-One+ robotic system for percutaneous coronary interventions — being acquired by Stereotaxis in 2026 for up to $45M. Most directly comparable peer as it operates in the same endovascular surgical robotics category with an overlapping customer base of interventional cardiologists.

2Biosense Webster (Johnson & Johnson)
TypeBroad incumbent
Description

Dominant EP franchise inside J&J offering CARTO 3 electroanatomical mapping and a broad ablation catheter portfolio. Comparable as it sets the standard for EP lab workflows that Stereotaxis must integrate with rather than replace, and represents the largest competitive threat in cardiac ablation.

3Abbott
TypeBroad incumbent
Description

Major cardiac mapping and ablation player with EnSite X system, and a global collaboration partner with Stereotaxis. Comparable because it both competes and integrates with Stereotaxis robotic systems in EP labs globally, defining much of the workflow ecosystem.

TypeBroad incumbent
Description

Large EP franchise with Rhythmia mapping and a leading RF and PFA ablation catheter portfolio. Comparable as a broad incumbent in cardiac ablation whose procedural workflow, mapping, and catheter choices compete for the same hospital capital and per-procedure budget as Stereotaxis.

TypeBroad incumbent
Description

Cardiac rhythm and ablation incumbent with its own cryoablation and PFA platforms. Comparable as a broad EP and cardiac device incumbent competing for the same hospital accounts and ablation procedure volumes.

6Acutus Medical
TypeEmerging player
Description

Developer of the AcQMap non-contact mapping system, which has been demonstrated in integrated procedures with Stereotaxis robotic navigation. Comparable as an emerging EP mapping player whose system competes for mapping share within the same lab where Stereotaxis robots operate.

TypeEmerging player
Description

Pulsed Field Ablation specialist partnered with Stereotaxis to develop a robotic PFA system. Comparable as a focused emerging player in next-gen ablation whose technology will be navigated by Stereotaxis systems, making it a co-development partner and adjacent competitor in PFA.

TypeEmerging player
Description

Developer of the VIVO non-invasive arrhythmia localization technology, integrated with Stereotaxis RMN. Comparable as a small-cap emerging EP technology company whose products are designed to plug into the same robotic navigation workflows.

TypeEmerging player
Description

Provider of AI-derived preoperative 3D mapping from CT/MRI integrated with Stereotaxis robotic navigation. Comparable as a niche emerging player whose mapping output feeds into the same robotic ablation procedures.

10MicroPort Scientific
TypeRegional player
Description

Shanghai MicroPort EP Medtech is Stereotaxis's China distribution and strategic partner, and parent of the CathBot vascular robotics JV with Robocath. Comparable as a regional EP and surgical robotics player with overlapping technology and customer base in the China market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stereotaxis

Surgical Robotics for Cardiac Electrophysiologystereotaxis.com

Stereotaxis develops robotic magnetic navigation systems and proprietary catheters for minimally invasive cardiac ablation, serving 100+ hospitals globally through direct enterprise sales supplemented by recurring catheter consumables and emerging digital surgery software.

What Stereotaxis does

Stereotaxis is a St. Louis-based medical technology company founded in 1990 that develops robotic systems for minimally invasive endovascular procedures, with its primary application in cardiac ablation to treat arrhythmias. Its core technology, Robotic Magnetic Navigation (RMN), uses computer-controlled magnetic fields to navigate catheters inside the heart with precision, stability, and reduced radiation exposure, differentiating it from manual catheter ablation. The company sells capital equipment — the Genesis RMN System and the newer semi-mobile GenesisX System — to hospitals and electrophysiology labs globally. These systems are complemented by a proprietary consumable catheter portfolio (MAGiC ablation catheter, MAGiC Sweep high-density mapping catheter, and Map-iT diagnostic catheters acquired via the 2024 Access Point Technologies deal) that drives recurring procedure-based revenue under a razor/razor-blade model. More recently, Stereotaxis has expanded into a digital surgery ecosystem with the Synchrony platform (FDA-cleared April 2026), which aggregates cath lab systems onto a consolidated 4K display, and the SynX cloud app for HIPAA/GDPR-compliant remote connectivity, training, and collaboration, opening a subscription revenue stream. Customers are hospitals and electrophysiology labs across more than 100 sites in the US, Europe, and Asia, sold through a direct enterprise field sales force supplemented by a strategic partnership with Shanghai MicroPort EP Medtech for China.

The business model combines one-time capital equipment sales, recurring single-use catheter consumables, and emerging subscription software revenue. The company is unprofitable but improving — operating losses narrowed to approximately ($22.1M) in 2025 from ($24.7M) in 2024 on revenue of $32.4M (up 20% YoY), with 2026 guidance above $40M. Capital has been raised through a $15M Consonance Capital financing in 2020, a $12.5M registered direct offering in July 2025, and a $50M ATM facility with Roth Capital in August 2025. The announced acquisition of Robocath (April 2026, up to $45M) would extend the platform into interventional cardiology and neurointerventions, and a collaboration with CardioFocus (October 2025) targets robotic Pulsed Field Ablation, a next-generation energy modality. CEO David Fischel has led the company since 2019 under a Tesla-inspired performance-based compensation structure.

Stereotaxis firmographics

Firmographics
Name
Stereotaxis
Legal name
Stereotaxis, Inc.
Website
https://stereotaxis.com
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
101–250 employees
Short description
Stereotaxis develops robotic magnetic navigation systems and proprietary catheters for minimally invasive cardiac ablation, serving 100+ hospitals globally through direct enterprise sales supplemented by recurring catheter consumables and emerging digital surgery software.
Ownership category
akta.pro rank

Stereotaxis industry classification

Industry
Product category
Surgical Robotics for Cardiac Electrophysiology
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHACAH
Remote Patient Monitoring (RPM) Platforms & Device Hubs (Connectivity/Gateways)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Robotic magnetic navigation
  • Cardiac ablation systems
  • Electrophysiology catheters
  • Surgical robotics
  • Interventional cardiology devices

Where Stereotaxis is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Stereotaxis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Robotic Surgical Systems: Capital equipment sales of Genesis and GenesisX robotic magnetic navigation systems to hospitals. Systems represent significant upfront capital expenditure for hospital cath labs.
  2. Catheter Consumables: Recurring revenue from proprietary ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in procedures with robotic systems. Razor/razor-blade model driving recurring consumable sales.
  3. Digital Surgery Software/Services: Revenue from Synchrony digital surgery platform and SynX cloud connectivity services. Company expects more than $3 million in standalone SynX revenues.
  4. Stock Sales (ATM Facility): Sales Agreement with Roth Capital Partners allowing sale of up to $50 million worth of common stock for working capital, R&D, and commercialization.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractCapital equipment - Robotic systems
Unit PricingPay-as-you-goCatheter consumables
SubscriptionAnnualSynX cloud connectivity

Go-to-market motion2 records

Distribution channels3 records

Marketing channels12 records

Stereotaxis product offering

Product offering

Core offering

Stereotaxis develops and sells Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—that use computer-controlled magnetic fields to navigate electrophysiology catheters inside the heart with precision and stability. The company also sells proprietary single-use ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in conjunction with the robotic systems, as well as the Synchrony digital surgery platform and SynX cloud connectivity app. These offerings are sold primarily to hospitals and cardiac electrophysiology labs for minimally invasive treatment of arrhythmias and coronary artery disease.

Product overview

Stereotaxis is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. The company's portfolio centers on Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—which use computer-controlled magnetic fields to precisely navigate catheters during cardiac ablation procedures. Complementing the robotic systems are differentiated catheters including MAGiC ablation catheters, MAGiC Sweep mapping catheters, and Map-iT diagnostic catheters (from the Access Point Technologies acquisition). The Synchrony digital surgery platform aggregates cath lab systems onto consolidated 4K displays, paired with the cloud-based SynX app for remote connectivity and collaboration. Together, these products form a comprehensive ecosystem addressing the interventional laboratory from robotic navigation to digital surgery enablement.

Differentiator

Problem solved

Functional benefit

Brands

  • Genesis: Robotic Magnetic Navigation System - designed as a powerful robotic magnetic navigation system with unprecedented responsiveness to physician control
  • GenesisX
  • Synchrony
  • SynX
  • MAGiC
  • MAGiC Sweep
  • Map-iT
  • Cardiodrive
  • Navigant

Products and services

  • Genesis Robotic Magnetic Navigation System The most powerful Robotic Magnetic Navigation System by Stereotaxis, featuring magnets held on flexible robotic arms for unprecedented physician control, increased system angulation, and improved performance and reliability compared to prior RMN systems. Sold as capital equipment to hospitals with electrophysiology labs.
  • GenesisX Robotic Magnetic Navigation System Next-generation semi-mobile Robotic Magnetic Navigation System combining Genesis speed and responsiveness with a form factor deployable in a cath lab over a weekend with no lab modifications required. Magnetic fields are shielded within the base when parked, allowing unrestricted use of the room.
  • Synchrony System Digital surgery platform that aggregates all cath lab systems and procedural information onto a consolidated 55-inch 4K ultra-high-definition display. Enables complete control of disparate systems through a single keyboard and mouse, declutters the lab environment, and supports future technological integration.
  • SynX Cloud-Based System Cloud-based app integrating with Synchrony display system for high-fidelity low-latency transmission of all lab information. Enables remote procedure monitoring, training, support, and collaboration in HIPAA/GDPR-compliant fashion requiring minimal hardware.
  • MAGiC Magnetic Interventional Ablation Catheter The world's first robotically navigated magnetic RF ablation catheter. Used with Stereotaxis robotic systems to provide catheter precision, stability, and flexibility for diagnosing and treating cardiac arrhythmias. Sold as single-use consumable driving recurring razor-blade revenue.
  • MAGiC Sweep Mapping Catheter The world's first robotically navigated high-density EP mapping catheter with 20 electrodes for rapid and highly detailed electroanatomical mapping. Enables mapping of complex anatomy with the inherent safety of an atraumatic catheter. Not CE marked; not available for sale in Europe.
  • Map-iT Diagnostic Catheters Portfolio of differentiated high-quality diagnostic EP catheters acquired through Access Point Technologies. Proprietary designs with quality materials and refined manufacturing deliver performance and durability for treating complex arrhythmias.

Quantifiable outcome

  • Over 150,000 patients treated globally with robotic technology
  • +4 more outcomes

Companies that use Stereotaxis

Customer profile

Named customers10 records

Segments1 record

Ideal customer profiles1 record

Stereotaxis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability5 records

Feature9 records

Stereotaxis partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • RobocathcoreStrategic or Co-development Partner · 15 April 2026Stereotaxis acquiring Robocath, a France-based surgical robot developer, for up to $45 million ($20M upfront + $25M contingent). Robocath develops R-One+ robotic technology for interventional cardiology and neurointerventions - the only robot commercially available in Europe for PCI. Expected to close mid-2026, operating as subsidiary.
  • CardioFocusmajorStrategic or Co-development Partner · 13 October 2025Collaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.
  • Access Point Technologies (APT)coreStrategic or Co-development Partner · 13 May 2024Stereotaxis acquired Access Point Technologies, a Minnesota-based developer and manufacturer of electrophysiology catheters. Transaction closed July 31, 2024. Acquisition enhances in-house catheter manufacturing capabilities, contributing approximately $5 million in annual revenue.
  • AbbottcoreTechnology or Integration · 24 May 2023Global collaboration combining Abbott's leading cardiac mapping systems (EnSite X, Ensite X EP System, AcQMap) with Stereotaxis' advanced robotic magnetic navigation technology. First integrated procedures completed in US at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
  • Shanghai MicroPort EP Medtech Co. Ltd.majorChannel Partner/ Reseller/ Distributor · 31 August 2021Strategic relationship with Shanghai MicroPort EP Medtech Co. Ltd. for China market expansion. China described as new 'geographic pillar' for commercial efforts. MicroPort joint venture with Robocath formed CathBot for vascular intervention robotics.
  • Osypka AGmajorStrategic or Co-development Partner · 9 May 2019Broad strategic collaboration with Osypka AG for designing and developing next-generation magnetic ablation catheter to be navigated using Stereotaxis' robotic technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Stereotaxis competitors and assessment

Company assessment

Direct peers

  • Robocath: French developer of the R-One+ robotic system for percutaneous coronary interventions — being acquired by Stereotaxis in 2026 for up to $45M. Most directly comparable peer as it operates in the same endovascular surgical robotics category with an overlapping customer base of interventional cardiologists.

Broad incumbents

  • Biosense Webster (Johnson & Johnson): Dominant EP franchise inside J&J offering CARTO 3 electroanatomical mapping and a broad ablation catheter portfolio. Comparable as it sets the standard for EP lab workflows that Stereotaxis must integrate with rather than replace, and represents the largest competitive threat in cardiac ablation.
  • Abbott: Major cardiac mapping and ablation player with EnSite X system, and a global collaboration partner with Stereotaxis. Comparable because it both competes and integrates with Stereotaxis robotic systems in EP labs globally, defining much of the workflow ecosystem.
  • Boston Scientific: Large EP franchise with Rhythmia mapping and a leading RF and PFA ablation catheter portfolio. Comparable as a broad incumbent in cardiac ablation whose procedural workflow, mapping, and catheter choices compete for the same hospital capital and per-procedure budget as Stereotaxis.
  • Medtronic: Cardiac rhythm and ablation incumbent with its own cryoablation and PFA platforms. Comparable as a broad EP and cardiac device incumbent competing for the same hospital accounts and ablation procedure volumes.

Emerging players

  • Acutus Medical: Developer of the AcQMap non-contact mapping system, which has been demonstrated in integrated procedures with Stereotaxis robotic navigation. Comparable as an emerging EP mapping player whose system competes for mapping share within the same lab where Stereotaxis robots operate.
  • CardioFocus: Pulsed Field Ablation specialist partnered with Stereotaxis to develop a robotic PFA system. Comparable as a focused emerging player in next-gen ablation whose technology will be navigated by Stereotaxis systems, making it a co-development partner and adjacent competitor in PFA.
  • Catheter Precision: Developer of the VIVO non-invasive arrhythmia localization technology, integrated with Stereotaxis RMN. Comparable as a small-cap emerging EP technology company whose products are designed to plug into the same robotic navigation workflows.
  • inHEART: Provider of AI-derived preoperative 3D mapping from CT/MRI integrated with Stereotaxis robotic navigation. Comparable as a niche emerging player whose mapping output feeds into the same robotic ablation procedures.

Regional players

  • MicroPort Scientific: Shanghai MicroPort EP Medtech is Stereotaxis's China distribution and strategic partner, and parent of the CathBot vascular robotics JV with Robocath. Comparable as a regional EP and surgical robotics player with overlapping technology and customer base in the China market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Stereotaxis social profiles

Digital presence

Stereotaxis compliance and trust

Trust signal

Compliance3 records

Stereotaxis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stereotaxis leadership team

Management profile

Number of profiles

Profiles1 record

Stereotaxis subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Stereotaxis funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stereotaxis M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stereotaxis

What does Stereotaxis do?

Stereotaxis develops and sells Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—that use computer-controlled magnetic fields to navigate electrophysiology catheters inside the heart with precision and stability. The company also sells proprietary single-use ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in conjunction with the robotic systems, as well as the Synchrony digital surgery platform and SynX cloud connectivity app. These offerings are sold primarily to hospitals and cardiac electrophysiology labs for minimally invasive treatment of arrhythmias and coronary artery disease.

Is Stereotaxis a public or private company?

Stereotaxis is a public company. It is classified as public and is currently operating.

When was Stereotaxis founded?

Stereotaxis was founded in 1990. It employs 101 to 250 people.

Where is Stereotaxis based?

Stereotaxis is headquartered in St Louis, United States, in the North America region.

How does Stereotaxis make money?

Four revenue lines are on record. Robotic Surgical Systems are the primary driver. The others are catheter Consumables, digital Surgery Software/Services and stock Sales (ATM Facility).

Who are Stereotaxis's main competitors?

Robocath is listed as a direct peer. Broad incumbents are Biosense Webster (Johnson & Johnson), Abbott, Boston Scientific and Medtronic. Emerging players are Acutus Medical, CardioFocus, Catheter Precision and inHEART. MicroPort Scientific is listed as a regional player.

Does Stereotaxis have an API?

No public API is recorded for Stereotaxis.

What industry is Stereotaxis in?

Stereotaxis's product category is Surgical Robotics for Cardiac Electrophysiology. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HDAAAIAC, Healthcare & Assistive Robotics. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerStereotaxis revenue up 20% to USD 8.9M in Q3 2026Stereotaxis reported Q3 2026 revenue of $8.9 million, up 20% year-over-year, with system revenue of $3 million and recurring revenue of $5.9 million. The company announced a convertible note financing of up to $24 million, with $12 million upfront, bringing pro forma cash to $16 million.TradingViewTD Cowen maintains Stereotaxis at Buy, lowers price target to $2 from $3TD Cowen maintained Stereotaxis at Buy and lowered its price target to $2 from $3, a 33.3% decrease. The price target implies an upside of 94.2% from the Nov 10 close of $1.03.Investing.comWhy is Stereotaxis stock sliding today?Stereotaxis stock fell 14.6% in morning trading after Q3 2026 results missed estimates, with an adjusted loss of $0.07 per share and revenue of $8.9 million versus $9.9 million forecast. A convertible note financing of up to $24 million raised dilution concerns, and TD Cowen cut its price target to $2.00.YahooWhat Stereotaxis (STXS) Said on Its Q3 Earnings CallStereotaxis reported Q3 revenue of $8.9 million, up 20% year over year, while net loss remained $6.5 million. The company received $12 million in convertible-note financing and expects profitability in 2027. MAGiC catheter supply constraints continue to limit procedures and sales.Seeking AlphaStereotaxis, Inc. (STXS) Q3 2026 Earnings Call TranscriptStereotaxis CEO David Fischel outlined near-term priorities for Q3 2026, focusing on two business model transformations. The first shift moves from capital systems with long sales and construction timelines to easily installed systems, making them more accessible.Dealroom.coStereotaxis secures up to $24M in convertible notes to bridge toward profitabilityStereotaxis, a St. Louis-based surgical robotics firm, secured up to $24 million in convertible notes, with $12 million closing and $12 million available after regulatory milestones. The notes carry 10% interest and convert at $1.21 per share, a 30% premium to the pre-closing VWAP. The financing aims to bridge the company to profitability.YahooStereotaxis Reports 2026 Third Quarter Financial Results & Business UpdatesStereotaxis reported Q3 2026 revenue of $8.9 million, up 20% year-over-year, with system revenue of $3 million up 60%. The company announced a convertible note financing of up to $24 million, with $12 million upfront. It expects growing recurring revenue and more consistent capital sales in coming quarters.Stock TitanStereotaxis robotic study: 100% clinical success in 20 casesStereotaxis reported 100% clinical success and no device-related adverse events in 20 first-in-human PCI procedures with its next-generation Robocath system. The study, led by Dr. Nejjari, showed 95% technical success with only one procedure requiring manual conversion. A manuscript is under review, and the company plans regulatory submissions.Business & FinancialCanon Medical And Stereotaxis Collaborate To Advance Robotic ElectrophysiologyCanon Medical Systems USA and Stereotaxis announced a collaboration to pair Canon's Alphenix interventional imaging platform with Stereotaxis' GenesisX robotic magnetic navigation system. The partnership aims to expand access to robotic electrophysiology and improve workflow, with further opportunities for advanced capabilities in electrophysiology and beyond.